サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1795375

全身性肥満細胞症治療の世界市場

Systemic Mastocytosis Treatment

出版日
ページ情報
英文 185 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.92円
全身性肥満細胞症治療の世界市場
出版日: 2025年08月21日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 185 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

全身性肥満細胞症治療の世界市場は2030年までに7億910万米ドルに達する見込み

2024年に5億3,090万米ドルと推定される全身性肥満細胞症治療の世界市場は、2030年には7億910万米ドルに達し、分析期間2024-2030年のCAGRは4.9%で成長すると予測されます。本レポートで分析したセグメントの1つであるAK-002治療は、CAGR 4.4%を記録し、分析期間終了までに3億520万米ドルに達すると予測されます。BLU-285治療分野の成長率は、分析期間中CAGR 5.4%と推定されます。

米国市場は1億3,960万米ドルと推定、中国はCAGR4.9%で成長予測

米国の全身性肥満細胞症治療市場は、2024年に1億3,960万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを4.9%として、2030年までに1億1,480万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.6%と4.2%と予測されています。欧州では、ドイツがCAGR 4.1%で成長すると予測されています。

世界の全身性肥満細胞症治療市場- 主要動向と促進要因まとめ

なぜ全身性肥満細胞症が精密医療で注目されているのか？

全身性肥満細胞症（SM）は、皮膚、骨髄、肝臓、脾臓などのさまざまな臓器における肥満細胞の異常蓄積を特徴とするまれな血液新生物です。本疾患は、臓器浸潤と肥満細胞メディエーター放出（例、ヒスタミン、トリプターゼ）の両方によって引き起こされる症状を伴い、緩徐型から侵攻性の亜型まで幅広いです。しばしばアナフィラキシー、消化管機能障害、骨痛を伴う複雑な臨床像を呈するため、早期診断と個別化治療が不可欠です。分子診断学の進歩、特にKIT D816V変異の同定は、より正確な疾患分類と予後を可能にしました。その結果、SMは現在、希少がん領域における標的治療開発の最前線にあり、テーラーメード治療の選択肢が検討され、承認されつつあります。

標的療法はどのように全身性肥満細胞症治療の状況を変えているのか？

KIT変異を標的とするチロシンキナーゼ阻害薬（TKI）の導入は、治療戦略を再定義しました。進行したSMに対して承認された選択的阻害剤であるアバプリチニブは、症状の緩和と疾患負担の軽減という点で顕著な臨床的有用性を示しています。もう一つのKIT標的治療薬であるミドスタウリンは、進行型SMに対する重要な治療薬です。抗IgE抗体や肥満細胞安定化剤などの併用療法や新規薬剤は、メディエーターに関連した症状や共存するアレルギー疾患を管理するために評価されています。さらに、免疫調節薬や新しいキナーゼ阻害薬の研究が、薬剤耐性やくすぶり続けるSM亜型に対処するために進行中です。変異負荷と疾患サブタイプに基づく個別化された投与戦略は、治療成績と忍容性をさらに向上させています。

SM患者の治療アクセスと疾患モニタリングはどこで改善されているのか？

専門の血液センターや希少疾患センターでは、ゲノム検査、集学的治療、長期的な患者モニタリングを組み合わせた包括的なSM治療プログラムを実施しています。疾患特異的なスコアリングツールがEHRに統合され、治療法の選択と進行の追跡が可能になっています。患者支援ネットワークは製薬会社と協力し、コンパッショネートユースや治験薬へのアクセス拡大を促進しています。デジタルプラットフォームは、特に専門医へのアクセスが限られている国々において、遠隔での症状追跡や治療反応をサポートしています。アレルギー専門医、皮膚科専門医、腫瘍専門医の間での認知度の向上は、タイムリーな介入への重要な障壁である診断潜伏期間の短縮に役立っています。また、世界のSM登録の確立は、臨床的洞察を向上させ、政策立案に情報を提供しています。

全身性肥満細胞症治療市場の成長はいくつかの要因によってもたらされる...

変異特異的標的治療薬の利用可能性、分子診断学の進歩、希少疾患治療インフラの拡大が市場を牽引しています。KIT標的TKIの承認と商業化により、進行SM患者に新たな治療時代が開かれました。希少がん保険償還制度や希少疾病用医薬品パイプラインへのSMの組み入れが進み、治療へのアクセスが向上しています。コンパニオン診断薬やバイオマーカーによるモニタリングツールの開発は、治療の精度と患者の転帰を向上させています。研究資金の増加、国際的な臨床共同研究、医師の意識の高まりは、総じてこの情勢に勢いを与えています。

セグメント

種類（AK-002治療薬、BLU-285治療薬、Brentuximab Vedotin治療薬、Crenolanib Besylate治療薬、その他の治療薬）、投与経路（経口投与薬、注射剤投与薬、局所投与薬）

調査対象企業の例

  • AB Science SA
  • AbbVie Inc.
  • Allakos Inc.
  • AstraZeneca
  • Bayer AG
  • Blueprint Medicines Corp.
  • Bristol-Myers Squibb Company
  • Cogent Biosciences Inc.
  • Deciphera Pharmaceuticals
  • Eli Lilly & Company
  • Glenmark Pharmaceuticals Ltd.
  • Hoffmann-La Roche Ltd.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Mallinckrodt Pharmaceuticals
  • Merck & Co. Inc.
  • Mylan NV（now Viatris）
  • Novartis AG
  • Pfizer Inc.
  • Sanofi Aventis
  • Teva Pharmaceutical Industries Ltd.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP38159

Global Systemic Mastocytosis Treatment Market to Reach US$709.1 Million by 2030

The global market for Systemic Mastocytosis Treatment estimated at US$530.9 Million in the year 2024, is expected to reach US$709.1 Million by 2030, growing at a CAGR of 4.9% over the analysis period 2024-2030. AK-002 Treatment, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$305.2 Million by the end of the analysis period. Growth in the BLU-285 Treatment segment is estimated at 5.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$139.6 Million While China is Forecast to Grow at 4.9% CAGR

The Systemic Mastocytosis Treatment market in the U.S. is estimated at US$139.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$114.8 Million by the year 2030 trailing a CAGR of 4.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.6% and 4.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Systemic Mastocytosis Treatment Market - Key Trends & Drivers Summarized

Why Is Systemic Mastocytosis Gaining Attention in Precision Medicine?

Systemic mastocytosis (SM) is a rare, hematologic neoplasm characterized by abnormal accumulation of mast cells in various organs such as the skin, bone marrow, liver, and spleen. The disease ranges from indolent forms to aggressive subtypes, with symptoms caused by both organ infiltration and mast cell mediator release (e.g., histamine, tryptase). The complex clinical presentation, often involving anaphylaxis, gastrointestinal dysfunction, and bone pain, makes early diagnosis and personalized treatment essential. Advances in molecular diagnostics-particularly the identification of KIT D816V mutations-have allowed for more accurate disease classification and prognosis. As a result, SM is now at the forefront of targeted therapy development in rare oncology, with a growing number of tailored treatment options being explored and approved.

How Are Targeted Therapies Changing the Systemic Mastocytosis Treatment Landscape?

The introduction of tyrosine kinase inhibitors (TKIs) targeting the KIT mutation has redefined treatment strategies. Avapritinib, a selective inhibitor approved for advanced SM, has shown significant clinical benefit in terms of symptom relief and disease burden reduction. Midostaurin, another KIT-targeted therapy, remains a key treatment for aggressive and advanced forms. Combination therapies and novel agents-such as anti-IgE antibodies and mast cell stabilizers-are being evaluated for managing mediator-related symptoms and co-existing allergic conditions. Additionally, research into immunomodulatory drugs and newer kinase inhibitors is ongoing to address drug-resistant or smoldering SM variants. Personalized dosing strategies, based on mutation load and disease subtype, are further improving therapeutic outcomes and tolerability.

Where Is Treatment Access and Disease Monitoring Improving for SM Patients?

Specialized hematology and rare disease centers are implementing comprehensive SM care programs that combine genomic testing, multidisciplinary care, and longitudinal patient monitoring. Disease-specific scoring tools are being integrated into EHRs to guide therapy selection and track progression. Patient advocacy networks are collaborating with pharmaceutical companies to facilitate compassionate use and expanded access to investigational therapies. Digital platforms are supporting remote symptom tracking and treatment response, especially in countries with limited access to specialists. Increasing awareness among allergists, dermatologists, and oncologists is helping reduce diagnostic latency, a key barrier to timely intervention. The establishment of global SM registries is also improving clinical insight and informing policy development.

The Growth in the Systemic Mastocytosis Treatment Market Is Driven by Several Factors…

It is driven by the availability of mutation-specific targeted therapies, advances in molecular diagnostics, and the expansion of rare disease treatment infrastructure. The approval and commercialization of KIT-targeting TKIs have opened a new therapeutic era for patients with advanced SM. Growing inclusion of SM in rare cancer reimbursement programs and orphan drug pipelines is improving treatment accessibility. Development of companion diagnostics and biomarker-guided monitoring tools is enhancing treatment precision and patient outcomes. Increased research funding, international clinical collaborations, and heightened physician awareness are collectively sustaining momentum in the systemic mastocytosis treatment landscape.

SCOPE OF STUDY:

The report analyzes the Systemic Mastocytosis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment, Other Treatments); Administration Route (Oral Administration, Injectable Administration, Topical Administration)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

  • AB Science SA
  • AbbVie Inc.
  • Allakos Inc.
  • AstraZeneca
  • Bayer AG
  • Blueprint Medicines Corp.
  • Bristol-Myers Squibb Company
  • Cogent Biosciences Inc.
  • Deciphera Pharmaceuticals
  • Eli Lilly & Company
  • Glenmark Pharmaceuticals Ltd.
  • Hoffmann-La Roche Ltd.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Mallinckrodt Pharmaceuticals
  • Merck & Co. Inc.
  • Mylan NV (now Viatris)
  • Novartis AG
  • Pfizer Inc.
  • Sanofi Aventis
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Systemic Mastocytosis Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Improved Diagnostic Rates and Classification Guidelines Drive Growth in Systemic Mastocytosis Treatment
    • Advancements in KIT Mutation Inhibitors Expand Therapeutic Possibilities for Advanced SM Subtypes
    • Rising Awareness Among Hematologists and Oncologists Fuels Earlier Treatment Initiation
    • Growth in Targeted Therapy Approvals Accelerates Market Entry of Novel Small Molecules
    • Expansion of Symptom Management Strategies Supports Broader Patient Coverage
    • Development of Non-Cytotoxic Therapies Improves Long-Term Tolerability and Outcomes
    • Emergence of Biomarker-Based Patient Stratification Strengthens Role of Personalized Medicine
    • Increased Enrollment in Clinical Trials Enhances Global Accessibility to Emerging Treatments
    • Improved Risk Classification Systems Facilitate Proactive Treatment for High-Risk Patients
    • Integration of Digital Tools for Symptom Tracking Supports Real-Time Disease Management
    • Demand for Oral Formulations With Lower Systemic Toxicity Drives Market Shift
    • Increased Awareness of Misdiagnosis and Underreporting Promotes Uptake of Confirmatory Testing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Systemic Mastocytosis Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Systemic Mastocytosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Systemic Mastocytosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for AK-002 Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for AK-002 Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for AK-002 Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for BLU-285 Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for BLU-285 Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for BLU-285 Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Brentuximab Vedotin Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Brentuximab Vedotin Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Brentuximab Vedotin Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Crenolanib Besylate Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Crenolanib Besylate Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Crenolanib Besylate Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Injectable Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Topical Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • JAPAN
    • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • CHINA
    • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • EUROPE
    • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Systemic Mastocytosis Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Systemic Mastocytosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • FRANCE
    • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • GERMANY
    • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • REST OF WORLD
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of World 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of World Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of World Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of World 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030

IV. COMPETITION